Invitrogen to Split Stock | GenomeWeb
NEW YORK (GenomeWeb News) – Invitrogen announced yesterday that its board of directors has approved a two-for-one stock split.
 
The Carlsbad, Calif.-based firm said that shareholders of record on May 16 will receive on May 27 one additional share for each share held. The company had approximately 48.9 million shares of common stock outstanding as of the end of the first quarter on March 31.
 
Invitrogen’s shares closed at $93.57 in Wednesday trade on the Nasdaq.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.